5 Best Long-term Stocks To Buy For High Returns

3. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Number of Hedge Fund Investors in Q2 2023: 53

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a biotechnology firm that seeks to leverage gene therapies to treat serious diseases. It’s another stock that is rated Strong Buy on average, and the average analyst share price target of $180.61 sets a massive $62 share price upside over the current share price of $117.96.

After digging through 910 hedge funds for their second quarter of 2023 shareholdings, Insider Monkey found 53 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) investors. Kurt Von Emster’s VenBio Select Advisor is the biggest investor among these as it owns $529 million worth of shares.

Follow Sarepta Therapeutics Inc. (NASDAQ:SRPT)